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Abstract
Background: The focal adhesion protein p130Cas (Cas) activates multiple intracellular signaling pathways upon
integrin or growth factor receptor ligation. Full-length Cas frequently promotes cell survival and migration, while its
C-terminal fragment (Cas-CT) produced upon intracellular proteolysis is known to induce apoptosis in some
circumstances. Here, we have studied the putative role of Cas in regulating cell survival and death pathways upon
proteasome inhibition.
Results: We found that Cas-/- mouse embryonic fibroblasts (MEFs), as well as empty vector-transfected Cas-/- MEFs
(Cas-/- (EV)) are significantly resistant to cell death induced by proteasome inhibitors, such as MG132 and
Bortezomib. As expected, wild-type MEFs (WT) and Cas-/- MEFs reconstituted with full-length Cas (Cas-FL) were
sensitive to MG132- and Bortezomib-induced apoptosis that involved activation of a caspase-cascade, including
Caspase-8. Cas-CT generation was not required for MG132-induced cell death, since expression of cleavage-
resistant Cas mutants effectively increased sensitivity of Cas-/- MEFs to MG132. At the present time, the domains in
Cas and the downstream pathways that are required for mediating cell death induced by proteasome inhibitors
remain unknown. Interestingly, however, MG132 or Bortezomib treatment resulted in activation of autophagy in
cells that lacked Cas, but not in cells that expressed Cas. Furthermore, autophagy was found to play a protective
role in Cas-deficient cells, as inhibition of autophagy either by chemical or genetic means enhanced MG132-
induced apoptosis in Cas-/- (EV) cells, but not in Cas-FL cells. Lack of Cas also contributed to resistance to the
DNA-damaging agent Doxorubicin, which coincided with Doxorubicin-induced autophagy in Cas-/- (EV) cells. Thus,
Cas may have a regulatory role in cell death signaling in response to multiple different stimuli. The mechanisms by
which Cas inhibits induction of autophagy and affects cell death pathways are currently being investigated.
Conclusion: Our study demonstrates that Cas is required for apoptosis that is induced by proteasome inhibition,
and potentially by other death stimuli. We additionally show that Cas may promote such apoptosis, at least
partially, by inhibiting autophagy. This is the first demonstration of Cas being involved in the regulation of
autophagy, adding to the previous findings by others linking focal adhesion components to the process of
autophagy.
Background
The ubiquitin-dependent proteasome system maintains
normal cellular function by eliminating aberrant pro-
teins in response to extracellular stimuli. Proteasome
inhibition has also emerged as part of adjuvant therapy
to increase sensitivity of cancer cells to chemotherapeu-
tic agents. Recently, the proteasome inhibitor Bortezo-
mib (Velcade™) was approved by the FDA for
treatment of relapsed multiple myeloma and mantle cell
lymphoma. Mechanisms underlying proteasome inhibi-
tion-mediated cell death are not well understood.
Focal adhesion protein p130Cas (Cas) is a multi-
domain docking protein, with an N-terminal SH3
domain, a central “substrate domain” consisting of mul-
tiple SH2-domain binding motifs (Tyr-x-x-Pro), and a
“Src-binding domain” near the C-terminus [1]. Follow-
ing integrin activation or growth factor stimulation, Cas
interacts with several protein partners and regulates cel-
lular events, such as migration, proliferation, and survi-
val [2]. Most notably, the adaptor protein Crk is a
primary docking partner and its association with
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tion and promotes tumor cell invasion [3]. In addition to
regulating cell motility, Cas can also relay survival signals
from the extracellular matrix to the nucleus [2]. It has
been reported that Cas confers resistance to anticancer
drugs such as Doxorubicin and tamoxifen via activation
of signaling pathways mediated by various kinases,
including Src, EGFR, Akt and ERK1/2 [4,5]. Ta et al.
observed that human breast cancer cell lines demonstrate
varying sensitivity to Doxorubicin, possibly due to vari-
able expression levels of Cas [5]. In fact, Cas expression
is considered a useful prognostic marker for patients
with primary or metastatic breast cancer [4]. Signaling
via the Cas/Crk complex also promotes cell survival via
activation of ERK and Rac pathways [6,7], and it has been
reported that uncoupling of Cas and Crk is required for
Abl-mediated apoptosis to take place [8].
While Cas frequently appears to signal pro-survival,
increasingly literature demonstrates that the C-terminal
domain of Cas that is released by proteolysis may play
an opposing role. For example, etoposide treatment of
HeLa cells elicits apoptosis accompanied by Cas clea-
vage, yielding a C-terminal 31 kD fragment (Cas-CT).
Specifically, Cas exhibits c l e a v a g ef i r s ta ts i t eA s p
416
yielding a C-terminal 74 kD product. Subsequent clea-
vage of this fragment at Asp
748 results in the generation
of the C-terminal 31 kD fragment during etoposide-
induced apoptosis, and replacement of Asp
748 with a
glutamic acid residue blocks the 31 kD Cas-CT produc-
tion in this system [9]. Notably, the 31 kD fragment has
been found to physically interact with the transcription
factor E2A in the nucleus and repress its activity, pre-
venting E-box binding to E2A and thus inhibiting E2A-
mediated p21
WAF1/CIP1 transcription and promoting
apoptosis [10]. Similar observations have been reported
on the death-promoting ability of another Cas family
member, human enhancer of filamentation (HEF1),
which requires generation of a C-terminal 28 kD frag-
ment [11].
Several additional pro-apoptotic stimuli, such as
detachment-induced cell death (also known as anoikis),
UV irradiation and treatment with anticancer drugs, can
induce Cas cleavage as well [12-14]. Both caspase and
calpain inhibitors can each partially block Cas cleavage,
but cleavage is not completely inhibited when these two
inhibitors are combined [9,14], suggesting that addi-
tional mechanisms are involved in Cas cleavage. This
notion is supported by a study demonstrating that
Smad3 interacts with HEF1 and mediates its cleavage
upon TGF-b stimulation [15]. In this case, HEF1 degra-
dation was inhibited by the proteasome inhibitor lacta-
cystin but not by the caspase inhibitor Z-VAD.
Here, we used several different cell death assays to
show that Cas is crucial for mediating cell death that
takes place upon proteasome inhibition. We found that
proteasome inhibition induces cell death in cells that
express Cas, but not in those that lack Cas expression.
Interestingly, inhibition of autophagy in Cas -/- MEFs
enhanced proteasome inhibition-induced cell death in
these cells. We also demonstrate that accumulated Cas-
CT plays only a minor role in MG132-induced cell
death. Thus, our studies uncover a novel role for Cas in
mediating proteasome inhibition-induced cell death, and
suggest that Cas may do so, at least partially, by inhibit-
ing autophagy. Intriguingly, we found that reduced levels
of Cas offer protection against cell death induced by the
DNA-damaging agent Doxorubicin, too, and this protec-
tion again coincides with induction of autophagy. Com-
bined with the findings by Ta et al.n o t i n gt h a t
overexpression of Cas results in chemoresistance [5],
our results suggest that Cas may have a universal yet
complex regulatory role in cell death signaling in
response to multiple different stimuli, perhaps deter-
mined by Cas gene/protein dosage.
Results
Cas mediates proteasome inhibition-induced cell death
Cas has been shown to regulate cell death pathways in
response to various anticancer agents, and we, therefore,
decided to examine its potential role in proteasome inhi-
bition-mediated cell death. To determine the role of Cas
in proteasome inhibition-induced cell death, Cas -/-
MEFs that had been stably transfected with either empty
vector (Cas-/- (EV)), or full-length wild-type Cas (Cas-
FL), were treated with proteasome inhibitors MG132 or
Bortezomib. As expected, MG132 or Bortezomib-treated
Cas-FL cells became round and detached under phase-
contrast microscope, indicative of proteasome inhibition-
induced cell death. Surprisingly, Cas-/- (EV) cells were
found to be resistant to proteasome inhibitor-induced
cell death (Figure 1A). To further compare the sensitivity
to proteasome inhibitors of Cas-/- (EV) and Cas-FL cells,
we undertook MTS assay measurements and found that
both MG132 and Bortezomib effectively killed wild-type
mouse embryonic fibroblasts (WT MEFs) and Cas-FL
MEFs in a dose-dependent fashion, while Cas-/- (EV)
cells were relatively resistant to these compounds (Figure
1B). To control for differences related to selection of sta-
bly transfected clonal cell lines, we also assayed non-
transfected primary Cas-/- MEFs and observed effects
similar to Cas-/- (EV) cells following treatment with var-
ious concentrations of MG132 or Bortezomib (data not
shown). Importantly, proteasome activity assay demon-
s t r a t e dt h a tp r o t e a s o m ea c t i v ity is equally inhibited in
Cas-/-(EV) and Cas-FL cells in response to MG132 treat-
ment. As such, differences in drug update or metabolism
do not appear to contribute to the cell survival differ-
ences observed in the two cell types (data not shown).
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shRNAs to specifically knock-down Cas expression in
human 293T and HeLa cells. As shown in Figure 1C, D,
two independent Cas shRNAs reduced Cas expression
by about 65% in the two cell lines. Concomitant with
this, about 50% reduction (demonstrating cell viability
percentile change from 60% to 80%, and cell death per-
centile change from 40% to 20%) was observed in
MG132-induced cell death, when Cas shRNA-trans-
fected 293T cells were compared to mock-transfected
cells or to cells transfected with empty vector or control
shRNA (Figure 1C). Likewise, Bortezomib-induced cell
death was reduced by about 45% in Cas shRNA-trans-
fected 293T cells (demonstrating cell viability percentile
change from 55% to 75%, and cell death percentile
change from 45% to 25%) (Figure 1C). Similarly, knock-
d o w no fC a sb ys h R N Ar e d u c e dM G 1 3 2 - i n d u c e dc e l l
death by about 40% (demonstrating cell viability percen-
tile change from 65% to 80%) in HeLa cells (Figure 1D).
Thus, these results suggest that proteasome inhibition-
induced cell death takes place in Cas-dependent manner
in different cell lines.
Our preliminary studies demonstrated that Cas levels
may control cellular responsiveness to other apoptotic
stimuli, too. While Ta et al. have found that overexpres-
sion of Cas confers resistance to Doxorubicin in breast
cancer cells [5], we found that complete lack of Cas
expression also reduces cellular responsiveness to
Doxorubicin, although not to the same extent than cel-
lular responsiveness to proteasome inhibitors. Thus,
about 37% reduction (demonstrating cell viability per-
centile change from 45% to 65%, and cell death percen-
tile change from 55% to 35%) was observed in 2.5 μM
Doxorubicin-induced cell death, when Cas-/- (EV) cells
were compared to Cas-FL cells (Additional file 1). These
preliminary results suggest that the role of Cas in drug
resistance may be more universal, but also more compli-
cated than previously anticipated, and suggest the intri-
guing possibility that gene and protein dosage may be
emerging as a major mechanism to control distinct bio-
logical events in case of Cas (see Discussion).
MG132-induced cell death is due to apoptosis
Proteasome inhibition reportedly induces cell death by
activating cell type-dependent signaling pathways. To
determine pathways underlying cell death in MG132-
treated MEFs, we treated Cas-FL and WT MEFs with
the pan-caspase inhibitor Z-VAD-FMK and observed
that the treatment largely prevented MG132-induced
cell death in a dose-dependent manner (Figure 2A), sug-
gesting that caspase-mediated apoptosis causes MG132-
induced cell death in this system. An ELISA assay mea-
suring nuclear DNA fragmentation as an indication of
apoptosis demonstrated that detectable apoptosis takes
place within 12 hours in MG132-treated Cas-FL cells,
and that the observed apoptosis was at maximal levels
Figure 1 Cas is required for proteasome inhibition-induced cell death. (A) Cas-/- (EV) and Cas-FL cells cultured in 60 mm dishes were
treated with vehicle, or MG132, or Bortezomib overnight, and the images were obtained under phase contrast microscope. Scale bar, 25 μm. (B)
Cell viability measurement by MTS assay. MEFs grown in 96-well plates were treated with different concentrations of the proteasome inhibitors
MG132 or Bortezomib for 16 hours. A total of 20 μl of MTS reagent was added to each well and incubated for another two hours. Absorbance
at 490 nm was detected on a plate reader. The data presented depict the MEAN ± SE from three independent experiments. (C and D), 293T
cells (C) or HeLa (D) cells transiently transfected with Cas shRNAs, control shRNA or empty vector, were treated with MG132 or Bortezomib for
16 hours, then assayed and results are presented as in panel A. shRNA-mediated reduction of Cas expression is shown in immunoblot.
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assay, we also observed that both 1 μMa n d5μM
MG132 could induce apoptosis in both Cas-FL and WT
MEFs, but not in Cas-/- (EV) cells, indicating that
MG132-elicited cell apoptosis requires Cas expression
(Figure 2C).
We next treated Cas-FL cells with different concentra-
tions of Z-VAD-FMK to examine its effect on MG132-
and Bortezomib-mediated apoptosis. As shown in Figure
2D, 10 μM Z-VAD-FMK had little effect on apoptosis,
20 μM Z-VAD-FMK blocked it by 70 to 90%, and 30
and 40 μM Z-VAD-FMK completely prevented MG132-
and Bortezomib-induced apoptosis. We additionally
evaluated cell viability using a live-dead cell staining
assay, and found that a portion of MG132-treated Cas-
FL cells were ethidium homodimer positive indicative of
cell death, which was not observed in the presence of Z-
VAD-FMK (Figure 2E). This further supports the notion
that proteasome inhibition-induced cell death in Cas-
expressing cells is due to caspase-mediated apoptosis.
Caspase signaling underlies MG132-induced apoptosis of
MEFs
Our data above indicate that the caspases likely mediate
MG132-induced MEF cell death, and we, therefore, ana-
lyzed caspase activation in MEFs by immunoblot analy-
sis. As shown in Figure 3A, 1 μM MG132 elicited
robust PARP cleavage in both Cas-FL and WT MEFs,
while it had little effect on Cas-/- (EV) cells (upper
panel). Consistently, PARP cleavage was weakly detected
Figure 2 MG132 induces apoptosis in Cas-expressing cells. (A) MTS assay to determine viability of Cas-/- (EV), Cas-FL and WT MEFs treated
with 1 μM MG132 and various concentrations of Z-VAD-FMK for 16 hours. (B) Apoptosis assay. Cas-FL MEFs were treated with 1 μM MG132 for
different times and lysed. A total of 5 μg of protein from each lysate was used in the cell death ELISA assay (see “Methods”). Results are means ±
SE from three independent experiments. (C) Cas-/- (EV), Cas-FL and WT MEFs were treated with 1 or 5 μM MG132 for 16 hours, and apoptosis
was monitored as in B. (D) Cas-FL MEFs were treated for 16 hours with MG132 (upper panel) or Bortezomib (lower panel) concomitant with
increasing concentrations of Z-VAD-FMK as indicated, and apoptosis was monitored as above. (E) Cell viability assay by live-dead staining. Cas-FL
MEFs treated with MG132 ± 30 μM Z-VAD-FMK for 16 hours were stained with calcein (green) and ethidium homodimer (EthD, red), and images
were obtained under fluorescence microscope.
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peak response occurred around 16 hours post-treatment
(Figure 3A, lower panel). Cleavage of “effector” cas-
pases-3 and -6, and “initiator” caspase-9 was readily
detected in both MG132-treated Cas-FL and WT MEFs
but not in Cas-/- (EV) cells (Figure 3B). MG132 concen-
t r a t i o na sh i g ha s5μM did not induce cleavage of cas-
pases-3, -6, and -9 in Cas-/- (EV) cells. We confirmed
that caspases-3/7 were activated by MG132 in Cas-FL
and WT MEFs using a luciferase-based luminescence
assay, and this activation was completely blocked by Z-
VAD-FMK (Figure 3C).
Release of mitochondrial cytochrome c into the cyto-
sol stimulates formation of the apoptosome to activate
caspases-3, -6, -7 and -9. To determine whether mito-
chondrial alteration occurs in MG132-treated MEFs, we
Figure 3 MG132 induces caspase cascade activation in Cas-expressing cells. (A and B) Immunoblots showing cleavage of PARP (A) or
caspases (B) in Cas-/- (EV), Cas-FL and WT MEFs treated with 1 or 5 μM MG132 for 16 hours as indicated. In the bottom panel in (A), Cas-FL cells
were treated with 1 μM MG132 for times indicated, to assess time-course for PARP cleavage. (C) Caspase-3/7 activity assay was carried out using
the Caspase-Glo
® 3/7 Assay kit in MEFs treated with or without 1 μM MG132 for 16 hours. Sample luminescence was measured, and
luminescence activity (RLU) was normalized by undertaking parallel MTS assays and evaluating cell number in untreated samples to reflect
caspase activity. (D) Cas-/- (EV), Cas-FL and WT MEFs treated with 1 μM MG132 were lysed, and separated into cytosolic and mitochondrial
fractions, followed by immunoblot to detect the release of cytochrome c from mitochondria to cytosol. Tubulin and VDAC served as cytosolic
and mitochondrial markers, respectively to assess purity of the fractions. (E) Caspase-8 activity was determined using the Caspase-Glo
® 8 Assay
kit in MG132-treated Cas-/-(EV) and Cas-FL MEFs, and luminescence was examined as in C. (F) The caspase-8 inhibitor Z-IETD-FMK (25 μM) was
used with various concentrations of MG132 to determine caspase-8 involvement in Cas-FL MEFs death, as measured by the MTS assay. (G) HeLa
cells stably transfected with Caspase-8 shRNA or control shRNA were treated with the indicated concentrations of the proteasome inhibitors
MG132 or Bortezomib for 16 hours, and cell viability was determined by MTS assay. shRNA-mediated reduction of Caspase-8 expression is shown
in the immunoblot.
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immunoblotting. MG132 treatment significantly
increased cytosolic cytochrome c levels in both Cas-FL
and WT MEFs but not in Cas-/- (EV) cells, suggesting
that the release of cytochrome c from mitochondria was
involved in MG132-induced, Cas-dependent apoptosis
(Figure 3D). Since caspase-8 also mediates apoptosis
and functions upstream of “effector” caspases, we under-
took a luminescence-based caspase-8 activation assay
and found that caspase-8 activation was dramatically
induced in MG132-treated Cas-FL cells, but only weakly
induced in Cas-/- (EV) cells (Figure 3E). Treatment with
the caspase-8-specific inhibitor Z-IETD-FMK signifi-
cantly protected Cas-FL MEFs from MG132-induced
death in MTS assays, suggesting caspase-8 involvement
in this process (Figure 3F). Furthermore, when Caspase-
8 expression was reduced by shRNA in HeLa cells, these
cells became resistant to both MG132 and Bortezomib
a ss h o w ni nt h eM T Sa s s a yi nF i g u r e3 G .T a k e n
together, our studies demonstrate activation of the cas-
pase cascade, including activation of the apical caspase-
8, upon MG132-treatment in Cas-expressing cells, but
not in cells that are deficient of Cas.
MG132 induces Cas cleavage in apoptotic cells
Previous studies have reported that several focal adhe-
sion proteins, including FAK, paxillin and Cas, undergo
cleavage (and subsequent degradation) during cellular
apoptosis [13,16]. Here, we found that Cas cleavage
takes place in Cas-FL cells and WT MEFs upon MG132
treatment, yielding multiple fragments including the
Cas-CT fragment (Figure 4A). Time-course analysis
showed that this fragment was detectable 4 hours after
MG132 treatment in Cas-FL MEFs, markedly increased
thereafter, and reached maximal levels at 16 hours post-
treatment (Figure 4B), in concordance with the patterns
of PARP cleavage and cell apoptosis (Figures 3A and 2B,
respectively). Overall, these observations suggest a posi-
tive correlation between Cas cleavage, caspase activation
and cellular apoptosis.
Since Z-VAD-FMK prevents MG132-induced cell
death (Figures 2A, E and 3C), we next investigated its
effect on Cas cleavage. As shown in Figure 4C (left
panel), Z-VAD-FMK did not alter the generation nor
accumulation of Cas-CT seen in Cas-FL MEFs treated
with MG132, suggesting that caspase inhibition alone is
not sufficient to prevent Cas-CT generation and accu-
mulation in proteasome-inhibited cells. In control
experiments, treatment with staurosporine, a potent
inducer of apoptosis, caused severe cell death in Cas-FL
cells, resulting in significant degradation of the full-
length Cas protein. Interestingly, Cas-CT was hardly
detected in these cells, and levels of full-length Cas were
greatly reduced (Figure 4C, right panel). In the presence
of MG132, however, proteasome-mediated Cas degrada-
tion was prevented and subsequently more intact full-
length Cas and Cas-CT were detected in staurosporine-
treated cells (Figure 4C, right panel). These data com-
bined indicate that both intact Cas and Cas fragments
are subject to proteasomal degradation during apoptosis
(induced here by either MG132 or staurosporine treat-
ment) and that upon proteasome inhibition, Cas and
Cas fragments (including Cas-CT) appear to accumulate
in cells.
As noted in the Introduction, Cas cleavage at sites
Asp
416 and Asp
748 precedes the generation of the 31 kD
Cas-CT fragment during etoposide-induced apoptosis
[9]. To determine the putative functional role of Cas-CT
in MG132-induced cell death, we stably expressed wt
Cas or Cas mutants containing point mutations in either
one or both codons at those two sites (D416E or
D748E) in Cas-/- MEFs. We then compared MG132-
induced signaling events in these transfected MEFs. In
agreement with a previous report [9], we found that the
cleavage of the p130Cas-D416E mutant in apoptotic
cells still took place, which resulted in increased levels
of Cas-CT upon MG132 treatment. Both the D748E
mutant and the D416/748E double mutant were resis-
tant to such cleavage, and no Cas-CT generation was
detected in cells expressing these mutants following
MG132 treatment (Figure 4D). Expression of both single
and double Cas mutant proteins, as well as of wt Cas,
significantly increased MG132-induced cleavage of
PARP and caspase-3 in Cas-/- MEFs, indicating promo-
tion of apoptosis (Figure 4E). Consistently, all the three
Cas mutants along with wt Cas effectively mediated
MG132-induced apoptosis, based on cell death ELISA
(Figure 4F) and cell viability (Figure 4G) assays.
Of note, Kim et al. have shown that p21
WAF1/CIP1
downregulation is responsible for Cas-CT-mediated
apoptosis in etoposide-treated HeLa cells [10]. In our
study, expression of full-length Cas or of these cleavage-
resistant mutants increased p21
WAF1/CIP1 expression in
both untreated and MG132-treated MEF cells (Figure
4E), rather, suggesting that p21
WAF1/CIP1 downregulation
does not underlie MG132-induced apoptosis in this cell
type. All these results indicate that, unlike the require-
ment for Cas-CT generation in etoposide-mediated
apoptosis, generation of Cas-CT is not necessary for Cas
to mediate MG132-induced cell death.
Autophagy protects Cas-/- (EV) cells from MG132-induced
apoptosis
Autophagy can be induced by numerous cellular stres-
ses, such as nutrition deprivation, hypoxia and protea-
some inhibition. Conversion of the mammalian protein
LC3-I, the homologue of yeast Atg8, to the autophago-
some-associated LC3-II is a hallmark of autophagy [17].
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gosomal membrane, LC3-II staining goes from diffuse to
punctate staining and the protein shows increased gel
mobility after lipidation, which is commonly used in
autophagy detection [18]. We observed dramatic upre-
gulation of LC3-II following MG132 or Bortezomib
treatment in Cas-/- (EV) cells compared to Cas-FL
MEFs (Figure 5A), suggesting that proteasome inhibition
induces autophagy, but only in cells that lack Cas. To
support this notion, shRNA-mediated knockdown of
Cas expression in MG132-treated 293T cells also eli-
cited autophagy activation as evidenced by increased
LC3-II level in Cas-shRNA expressing cells, but not in
control-transfected 293T cells where LC3-II was only
weakly detected (Figure 5B). These biochemical observa-
tions were further confirmed by immunofluorescence
studies, which showed that MG132 treatment induced
punctate appearance of endogenous LC3 in Cas-/- (EV)
cells, while LC3 remained diffusely distributed in
MG132-treated Cas-FL MEFs (Figure 5C).
Figure 4 Cas cleavage during MG132-induced apoptosis. (A) Cell lysates from Cas-/- (EV), Cas-FL and WT MEFs treated with 1 μMM G 1 3 2
were used in immunoblot analysis to detect Cas cleavage using an anti-p130Cas monoclonal antibody. (B) Cas-FL MEFs were treated with 1 μM
MG132 for different times, and Cas cleavage was detected by immunoblot as in A. (C) Cas-FL MEFs were treated with 1 μM MG132, 25 μMZ -
VAD-FMK, or 20 nM staurosporine (STS) alone, or in combination as indicated, and Cas cleavage was detected as in A. (D and E) Pools of Cas-/-
MEFs stably transfected with control vector, or wt Cas, or Cas mutant D416E, or D748E, or the double mutant D416/748E, were treated with 1
μM MG132, and cleavage of Cas (in D) and of PARP and caspase-3 (in E) was detected by immunoblot. Additionally, p21 expression was studied
in E by immunoblot. (F and G) Apoptosis ELISA assay (in F) and MTS assay (in G) were used to examine cell viability of MG132-treated Cas -/-
MEFs expressing the constructs indicated.
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widely used marker for autophagy induction [19]. As
shown in Additional file 2, we observed that MG132
treatment results in a reproducible and significant
decline in p62 levels in MG132-treated Cas -/- (EV)
cells compared to Cas-FL cells, and in MG132-treated
HeLa cells in which Cas expression has been down-
regulated by Cas-specific shRNAs, compared to control-
shRNA-transfected cells. Finally, we found that Doxoru-
bicin treatment, similar to proteasome inhibitor treat-
ment, results in a more profound induction of
autophagy in Cas -/- (EV) cells compared to Cas-FL
cells, as measured by LC3-II and p62 immunoblotting
(Additional file 3). Taken together, enhanced cell survi-
val in Cas -/- (EV) cells in thep r e s e n c eo fM G 1 3 2a n d
Doxorubicin appears to correlate with increased levels
of autophagy.
Accumulation of LC3-II could be a consequence of
either enhanced autophagic flux, or be due to the inhibi-
tion of autophagic degradation of LC3 in MG132-trea-
ted Cas-deficient cells. Bafilomycin A1 (BAF), which is a
specific inhibitor of vacuolar type H+-ATPase and
therefore prevents autophagy at a late stage by inhibiting
fusion between autophagosome and lysosome, was uti-
lized to assess the autophagic flux in MG132-treated
cells. As shown in Figure 5D, treatment with BAF and
MG132 significantly increased LC3-II levels as com-
pared to treatment with either MG132 or BAF alone in
Cas-/-(EV) cells, suggesting that autophagic flux was
indeed increased in Cas-/-(EV) cells that had been
treated with MG132. In comparison, BAF caused similar
levels of LC3-II accumulation in the presence and
absence of MG132 in Cas-FL cells (Figure 5D).
It is known that autophagy can protect cells from
apoptosis under some circumstances [18]. In a detailed
time-course experiment, we found that induction of
autophagy took place in Cas-/- (EV) cells as early as six
hours post-MG132 treatment, while apoptosis was
detected in Cas-FL cells around eight to nine hours
after MG132 treatment (Figure 6A). This time-course
data suggested that autophagy might play a protective
role in MG132-treated Cas-/- (EV) cells and prevent
subsequent apoptosis from taking place. Both chemical
and genetic approaches were undertaken to study this
possibility. Upon treatment of Cas-/- (EV) cells with
chemical inhibitors of autophagy, such as chloroquine
(CHQ) or 3-methyladenine (3-MA), MG132-induced
PARP cleavage was enhanced (Figure 6B), suggesting
that autophagy indeed blocks apoptosis in these cells.
Inhibition of autophagy had a more limited effect on
Cas-FL cell apoptosis, as evidenced by minimal changes
in PARP cleavage (Figure 6B). Apoptotic ELISA assay
revealed similar results, as inhibition of autophagy by 3-
MA or CHQ significantly promoted apoptosis in
MG132-treated Cas-/- (EV) MEFs (Figure 6C, left
panel). In agreement with these results, the inhibitors
significantly enhanced MG132-induced cell death in
Cas-/- (EV) MEFs but not in Cas-FL cells, when cell via-
bility assays were utilized as a read-out (Figure 6C, right
panel).
Figure 5 MG132-induced autophagy in Cas-deficient cells. (A) Cas-/- (EV) and Cas-FL MEFs were treated with 1 μM MG132 or Bortezomib for
16 hours, and LC3-II expression was examined by immunoblot. Relative intensity of LC3-II was calculated by normalizing the untreated Cas-/- (EV)
control to a relative intensity of 1.0, and then dividing subsequent LC3-II band intensity by actin band intensity in the same treatment group
using densitometry. (B) 293T cells transiently transfected with Cas shRNAs were treated with 1 μM MG132, and LC3-II expression was examined
by immunoblot as in A. (C) LC-3 immunostaining in MG132-treated Cas-/- (EV) and Cas-FL MEFs. (D) Cas-/- (EV) and Cas-FL MEFs were treated
with 1 μM MG132 in the presence or absence of 10 nM Bafilomycin A1 (BAF), and LC3-II expression was examined as in A.
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Page 8 of 14Figure 6 Autophagy protection of MG132-treated Cas-deficient cells. (A) Time course of MG132-induced autophagy and apoptosis in Cas-/-
(EV) and Cas-FL MEFs. Cas-/- (EV) and Cas-FL MEFs were treated with 1 μM MG132 as indicated, and LC3-II expression and PARP cleavage were
examined by immunoblot. (B) Effect of autophagy on MG132-induced apoptosis. MG132-treated Cas-/- (EV) or Cas-FL cells were assayed by
immunoblot to detect the PARP cleavage in the presence of autophagy inhibitors 3-MA (10 mM) or CHQ (20 μM). (C) Apoptosis ELISA (left
panel) and MTS assay (right panel) were used to examine the effects of autophagy inhibition on MG132-induced cell death in Cas-/- (EV) and
Cas-FL MEFs. (D) Cas-/-(EV) and Cas-FL MEFs stably transfected with ATG5 shRNAs or control shRNA were treated with 1 μM MG132, and the
cleavage of PARP and caspase-3 was examined by immunoblot (right panel). ATG5 expression in the various cell lines as measured by
immunoblot is shown in the left panels. The effect of shRNA-mediated knockdown of ATG5 on LC3-II formation is shown in the middle panels,
as detected by immunoblot. (E) ATG5 shRNA-transfected MEFs were treated with 1 μM MG132, and cell death was examined by the apoptosis
ELISA assay (left panel) or by MTS assay (right panel).
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Page 9 of 14To further confirm these results, we used ATG5
shRNAs to block MG132-induced autophagy in Cas-
When autophagy was inhibited by these genetic means
(Figure 6D, middle panel), increased PARP and caspase-
3 cleavage were detected in Cas-/- (EV) MEFs treated
with MG132 (Figure 6D, right panel). Consistent with
this, blockade of autophagy by ATG5 shRNA signifi-
cantly promoted Cas-/- (EV) cell death as shown in
both apoptotic ELISA assays and in cell viability assays
(Figure 6E). Taken together, our results indicate a novel
role for Cas in mediating apoptosis downstream of pro-
teasome inhibition, and suggest that Cas may do so, at
least partially, by inhibiting MG132-induced autophagy.
Discussion
Proteasome inhibition promotes cell death via different
pathways, depending on cell type and signaling context
[20-25]. Proteasome inhibition has also emerged as part
of adjuvant therapy to increase sensitivity of cancer cells
to chemotherapeutic agents. The docking protein Cas in
turn has been previously shown to regulate cell death in
response to treatment with various anticancer therapeu-
tics, and thus understanding the potential role that Cas
may have in cell death events induced by proteasome
inhibition is of great interest.
We show here that Cas expression is required for
MG132 to induce cell death via the classical caspase-
mediated apoptotic pathway. Previous studies by others
have shown that various apoptotic agents stimulate clea-
vage and subsequent degradation of Cas. Furthermore, it
has been suggested that cleavage of Cas might be causal
to, rather than consequence of apoptosis [10]. In
MG132-induced apoptotic cells, the mechanism of Cas
cleavage and the functional significance thereof appear
to be more complicated than in the other apoptotic sys-
tems. Thus, we show here that MG132 induces Cas
cleavage as is seen with other apoptosis inducers. How-
ever, MG132 additionally promotes accumulation of
intact Cas protein and Cas fragments, including Cas C-
terminal fragment (Cas-CT), most likely by increasing
their stability. Z-VAD-FMK blocks MG132-induced
apoptosis and thus should antagonize Cas cleavage (if
caused by caspases), but we nevertheless detect compar-
able amounts of Cas-CT in Z-VAD-FMK-treated cells,
suggesting that proteases other than caspases are
involved in Cas cleavage in these conditions (Figure 4C).
Thus, we hypothesize that proteasome inhibition plays a
dual role in Cas degradation. On one hand, MG132
induces cell apoptosis and activation of caspases and
other cellular proteases, promoting Cas cleavage. On the
other hand, and perhaps more significantly, MG132
facilitates accumulation of cleaved Cas fragments by
increasing their stability. This latter notion is supported
by the observation that staurosporine induces robust
apoptosis in MEFs, promoting severe Cas degradation
with no detectable Cas-CT generation. Simultaneous
MG132 treatment, however, significantly increases the
accumulation of Cas-CT in staurosporine-treated MEF
cells (Figure 4C).
In our studies, Cas cleavage and Cas-CT generation
were not found to be required for MG132-induced cell
death, as cleavage-resistant Cas mutants D748E and
D416/748E effectively promoted MG132-induced cell
death without generation and accumulation of Cas-CT
(Figure 4D-G). As noted earlier, the Cas-CT cleavage
product has been found to induce apoptosis by suppres-
sing p21
WAF1/CIP1 expression [10]. Here, we observed
significant p21
WAF1/CIP1 accumulation in all MEFs trea-
ted with MG132, rather, regardless of Cas expression
(Figure 4E), further supporting the notion that Cas med-
iates MG132-induced cell death by a previously
unknown mechanism.
As noted in the Background section, overexpression of
Cas in cancer cells confers resistance to anticancer
drugs such as Doxorubicin. We have tested Doxorubicin
in an MTS assay in Cas-/- (EV) and Cas-FL cells, and,
curiously, found that similar to proteasome inhibitors,
Cas-/- (EV) cells demonstrate noticeable resistance to
Doxorubicin-induced cytotoxicity (Additional File 1, Fig-
ure S1). We speculate that in cancer cells, where Cas is
significantly overexpressed compared to normal physio-
logical levels, Cas overexpression induces aberrant acti-
vation of numerous survival pathways, including the PI
3-kinase/Akt cascade, thereby shifting the balance of
Bcl-2 family members towards survival [26]. In cells
with greatly reduced levels of Cas in turn, we speculate
that activation of pathways such as autophagy and possi-
bly others, contributes to drug resistance. As such, dif-
ferent levels of Cas protein appear to contribute to
qualitative differences in cellular signaling. Understand-
ing how these qualitative differences in signaling in
response to quantitative differences in Cas protein levels
take place are of great importance for future studies. Of
note, the concept of gene and protein dosage is emer-
ging as a major mechanism to control distinct biological
events for some oncogenes [27], and it is intriguing to
speculate that this might be true for Cas, too. Clearly,
more work is needed to explore this notion.
Autophagy is an adaptive stress response that can
both suppress cell death and promote it in the form of
autophagic (type II) cell death [28]. Crosstalk between
autophagy and apoptosis is complex. In response to the
same stress, cells can preferentially undergo either,
depending on stimulus intensity and thresholds for
either response [18]. When cells are exposed to stress
signals, autophagy may protect cells from cell death, and
its inhibition can promote cell death. For instance,
TRAIL-resistant colon carcinoma cells become
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Page 10 of 14sensitized and undergo apoptosis when autophagy is
inhibited by specific inhibitors or by Beclin siRNA [29].
In this study, we found that MG132 treatment induces
autophagy in Cas-/- (EV) cells and that autophagy
appears to protect these cells from apoptosis. This con-
clusion was supported by the following observations: 1)
MG132 treatment of Cas-/- (EV) cells induced conver-
sion of LC3-I to LC3-II, formation of LC3-containing
dot structures in the cytoplasm, and reduced levels of
p62, all typical markers of autophagy (Figures 5A, C and
S2); 2) Increased autophagic flux in these cells was con-
firmed by treating them simultaneously with Bafilomycin
and MG132, which resulted in accumulation of LC3-II
in Cas-/- (EV) cells but not in Cas-FL cells (Figure 5D);
3) When autophagy was blocked by two different chemi-
cal autophagy inhibitors, namely 3-MA (an inhibitor of
the earliest stage of autophagosome formation by inhibi-
tion of class III PI3K) or chloroquine ((CHQ), an inhibi-
tor of lysosomal acidification, blocking the fusion
between autophagosomes and lysosomes, the final step
in the autophagy pathway), or by genetic means using
ATG5 shRNA, PARP cleavage was significantly
enhanced in Cas-/- (EV) cells treated with MG132 (Fig-
u r e6 B ,D ) ;a n d4 )I na c c o r d a n c ew i t ht h er e s u l ti nF i g -
ure 5A that autophagy is minimally induced in MG132-
treated Cas-FL cells, inhibition of autophagy had limited
effects on Cas-FL cell apoptosis, as evidenced by PARP
cleavage (Figure 6B, D). At the present time, it remains
unclear how autophagy might protect Cas -/- cells from
apoptosis. However, we speculate that it might do so by,
for example, promoting clearance of toxic protein aggre-
gates formed as a result of proteasome inhibition [18].
Without this clearance mechanism, then, Cas-expressing
cells would succumb to apoptotic cell death.
While induction of autophagy appears to protect Cas
-/- (EV) cells from proteasome inhibition-induced cell
death, it is likely that other mechanisms contribute to
the survival, as well. Notably, it has been reported that
growth rate influences sensitivity to proteasome inhibi-
tors [30,31]. Indeed, the doubling time for Cas-/-(EV) is
27.6 hours, while it is 20.9 hours for Cas-FL cells during
exponential growth phase in tissue culture (Additional
file 4). At the present time the underlying mechanisms
for this difference or its impact on cell survival remain
unclear.
The precise mechanism by which autophagy occurs in
Cas-deficient cells but not in Cas-expressing cells in
response to proteasome inhibition remains unknown.
C a si sa ni m p o r t a n td o c k i n gp r o t e i nd o w n s t r e a mo f
integrin signaling. Integrin ligation to extracellular
matrix proteins upon cell attachment promotes cell sur-
vival, thus mediating anchorage-dependent cell growth,
and Cas has been found to be a positive regulator of
these survival pathways. Upon cell detachment and
integrin disengagement from the extracellular matrix,
cells undergo anoikis (= detachment-induced cell death).
Interestingly, cell detachment can also induce autop-
hagy, which offers protection from cell death and limits
anoikis [32]. Thus, lack of integrin signaling due to cell
detachment, or due to reduced levels of an integrin sig-
naling molecule, such as Cas as shown here, appears to
induce autophagy. At the present time, the molecular
link between reduced integrin signaling and enhanced
autophagy is lacking [33]. The focal adhesion protein
FIP200 interacts with ATG1, and becomes distributed to
autophagosomes under starvation conditions. In FIP200-
deficient cells, autophagy induction by various treat-
ments is abolished, and both stability and phosphoryla-
tion of ATG1 are impaired [34]. Similarly, the focal
adhesion protein paxillin can be phosphorylated by
ATG1 and becomes redistributed from focal adhesions
to the cytoplasm along with vinculin in mouse fibro-
blasts induced to undergo autophagy by nutrient depri-
vation [35]. Furthermore, paxillin is found to be
required for autophagosome formation, but that role is
not dependent on integrin signaling [35]. Interestingly,
the Cas SH3 domain reportedly targets Cas to focal
adhesions by interacting with paxillin (and FAK) [36].
Thus, translocation of the Cas-paxillin complex out of
focal adhesions, or release of paxillin from the complex,
may be important for autophagy to take place. This
notion is supported by our preliminary studies, where
we have observed that Cas -/- MEFs reconstituted to
express a form of Cas that lacks the SH3-domain (Cas-
ΔSH3 MEFs) demonstrate reduced PARP cleavage in
response to MG132-treatment compared to Cas-FL
MEFs (data not shown). Understanding whether this
observation is tied to autophagy, to Cas-paxillin complex
formation, and uncovering how Cas regulates autophagy
will be an important future objective in our studies.
Conclusions
Our study demonstrates a previously unidentified, novel
role of Cas in mediating cellular sensitivity to protea-
some inhibition and, perhaps, to other apoptotic stimuli
and sheds light on apoptosis-autophagy crosstalk.
Further studies on the mechanisms underlying the role
of Cas (and potentially other focal adhesion proteins) in
regulating apoptosis and autophagy could provide
important insights into molecular switches governing
cell death and survival.
Methods
Antibodies and reagents
Antibodies against PARP, caspase-3, -6, and -9, cyto-
chrome c, LC3 and ATG5 were from Cell Signaling
(Beverly, MA, USA); anti-p130Cas monoclonal antibody
used in immunoblot analysis was from Transduction
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Page 11 of 14Laboratories (Lexington, KY, USA); anti-tubulin mono-
clonal antibody was purchased from EMD Biosciences
(San Diego, CA, USA); anti- p21
WAF1/CIP1 antibody was
from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
and anti-p62 and anti-actin antibodies were from Sigma
(St. Louis, MO, USA). MG132, Bortezomib, Bafilomycin
A1, Doxorubicin, Z-VAD-FMK, and Z-IETD-FMK were
purchased from EMD Biosciences.
Cell culture and establishment of stably transfected lines
Cas knock-out MEF cells (Cas-/-), and Cas-/- MEFs
transfected with empty vector (Cas-/- (EV)), or reconsti-
tuted with wild-type (wt) full-length Cas (Cas-FL) were
generously provided by Dr. Sakai and have been
described before [37]. Cleavage-resistant Cas mutants
were created by replacing aspartic acid residues D416
and D748 in the motifs DVPD
416Ga n dD S P D
748G[ 9 ]
with glutamic acid residues using the Quick Change
Mutagenesis Kit (Stratagene, La Jolla, CA, USA). Cas-/-
MEFs were cotransfected with empty vector, with wt
Cas, or with plasmids encoding the Cas cleavage-resis-
tant mutants, along with pBabe-puro using Fugene HD
reagent (Roche, Indianapolis, IN, USA) and selected in
puromycin. Transfectant pools were used for experi-
ments. Cas and ATG5 shRNAs were obtained from Ori-
Gene (Rockville, MD, USA). 293T cells were transiently
transfected with Cas shRNA constructs, and then were
used in the assays 24 to 48 hours post transfection.
MEFs were transfected with ATG5 shRNA, and then
selected in the presence of puromysin to obtain stable
lines. All cells were cultured in DMEM containing 10%
FCS and 1% glutamine. Cells were routinely treated with
1 μM MG132 in growth medium overnight (16 hours)
prior to analysis if not otherwise indicated.
MTS assay
Cell viability was determined using a CellTiter 96 AQu-
eous Cell Proliferation Assay Kit (Promega, Madison,
WI, USA), which is based on measuring metabolic con-
version of MTS into aqueous soluble formazan. Briefly,
cells grown in 96-well plates were treated as described
in the figure legends. A total of 20 μl of MTS reagent
was added to each well and incubated for two hours, as
recommended by the manufacturer. Absorbance at 490
nm, which is proportional to the number of living cells,
was monitored using a plate reader (BioTek, Winooski,
VT, USA). Viability of vehicle-treated cells was set at
100%. All the experiments were carried out in triplicates
and repeated at least three times. The data are shown as
mean ± SE from at least three independent experiments.
Cell viability assay
MEFs grown on glass bottom microcenter dishes were
treated with MG132 and stained with esterase substrate
calcein-AM (1:2, 000) and ethidium homodimer-1
(EthD-1, 1:1, 000) in Live/Dead Cell Staining Kit (Invi-
trogen, Carlsbad, CA), according to the manufacturer’s
instructions. Images were obtained using a Zeiss fluores-
cence microscope (Zeiss, Thornwood, NY), and living
cells were scored by bright green fluorescence and dead
or dying cells by red-orange fluorescence.
Apoptosis ELISA assay
Apoptosis was quantified using a cell death detection
ELISA kit, which measures DNA fragmentation (Roche).
MEFs were treated as indicated in the figure legends,
and lysed in complete lysis buffer. A total of 5 μgo f
protein from each sample was used in each apoptosis
ELISA, according to the manufacturer’s instructions.
Absorbance at 405 nm was monitored using a plate
reader (BioTek). All the experiments were repeated at
least three times, and the data are shown as mean ± SE.
Caspase activity assay
Activation of caspases 3/7 and caspase 8 was determined
by using Caspase-Glo Assay kits (Promega) following
the manufacturer’s instructions. Cells grown in white-
walled 96-well plates were treated with MG132 for 16
hours. A total of 100 μl of Caspase-Glo reagent were
added to each well, thoroughly mixed, and incubated for
30 minutes. Sample luminescence was measured with a
plate-reading luminometer (Biotek). Luminescence activ-
i t yr e f l e c t e db yt h en u m b e ro fr e l a t i v el i g h tu n i t s( R L U )
was normalized by undertaking parallel MTS assays and
evaluating cell number in untreated samples.
Immunoblotting
Cell monolayers were treated as described in the figure
legends, lysed in modified RIPA lysis buffer (25 mM
Tris-HCl, pH7.4, 10% glycerol, 0.2% Triton X-100, 150
mM NaCl, 2 mM EDTA, 2 mM EGTA) containing a
protease inhibitor cocktail (Roche), and clarified by cen-
trifugation. Protein concentrations of each sample were
determined by Bradford assay. Equal amounts of protein
were resolved by SDS-PAGE, transferred to a nitrocellu-
lose membrane, blocked with 3% dry milk (Biorad, Her-
cules, CA) in TBS-Tween-20 and exposed to specific
primary antibodies as described for each experiment.
Antibody binding was detected using horseradish perox-
idase (HRP)-conjugated goat anti-rabbit or anti-mouse
secondary antibodies (Sigma) and enhanced chemi-lumi-
nescence (ECL, GE Healthcare, Piscataway, NJ). Tubulin
or actin served as the internal loading control.
Immunostaining of microtubule-associated protein light
chain 3 (LC3)
Cells grown in a Lab-Tek
® II Chamber Slide System
(Nalge Nunc International, Naperville, IL, USA) were
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formalin, cells were permeabilized in 0.2% Triton X-100
for 10 min. Then the cells were blocked in 2% BSA for
one hour, followed by the incubation with anti-LC3
antibody at 4°C overnight. Cells were then washed three
times with PBS and incubated with Alexa 488-conju-
gated secondary antibody at room temperature for one
hour. After three washings, slides were cover-slipped
using FluorSave mounting medium containing DAPI
and sealed with nail polish. Images were taken under a
Zeiss fluorescence microscope.
Mitochondrial fractionation
Cytosolic and mitochondrial extracts were prepared by
using a mitochondrial isolation kit from Pierce (Rock-
ford, IL, USA) following the manufacturer’s instructions
for differential centrifugation protocol. In brief, MEFs
treated with MG132 overnight were washed once with
PBS, and resuspended in 800 μl of buffer A containing
protease inhibitor cocktail. After adding buffer B, cells
were vortexed and incubated on ice. After adding buffer
C and mixing well, the mixtures were centrifuged at 700
g for 10 minutes at 4°C. The supernatants were sub-
jected to another centrifugation at 12, 000 g for 15 min-
utes at 4°C. The supernatants were then collected and
designated as cytosolic fractions. The pellets were
washed once with buffer C, then used as mitochondrial
fractions. In the following immunoblot, tubulin and
VDAC were used as markers for cytosolic and mito-
chondrial fractions, respectively.
Additional material
Additional file 1: Lack of Cas attenuates cell death in response to
Doxorubicin. MEFs grown in 96-well plates were treated with different
concentrations of Doxorubicin for 24 hours. Cell viability was measured
by MTS assay. The data presented depict the MEAN ± SE from three
independent experiments.
Additional file 2: MG132-induced autophagy in Cas-deficient cells
as measured by p62 levels. (A) Cas -/- (EV) and Cas-FL cells were
treated or not with 1 μM MG132 for 16 hours, and p62 expression was
examined by immunoblot. Relative intensity of p62 was calculated by
normalizing the untreated control in Cas -/- (EV) cells to a relative
intensity of 1.0, and then dividing subsequent p62 band intensity by
actin band intensity in the same treatment group using densitometry. (B)
HeLa cells transiently transfected with Cas shRNAs or control shRNA were
treated with 2.5 μM MG132 for 24 hours, and then assayed for p62
levels. The results (normalized to the untreated control) are presented as
in panel A.
Additional file 3: Doxorubicin-induced autophagy in Cas-deficient
cells. Cas -/- (EV) and Cas-FL cells were treated or not with 2 μM
Doxorubicin for 24 hours, and the expression of p62 and LC3-II was
examined by immunoblot. Relative intensities of p62 and LC3-II were
calculated by normalizing the untreated control in Cas -/- (EV) cells to a
relative intensity of 1.0, and then dividing subsequent p62 or LC3-II
bands intensity by actin bands intensity in the same treatment group
using densitometry.
Additional file 4: Growth rate of Cas-/- (EV) and Cas-FL cells. Cas-/-
(EV) and Cas-FL cells were cultured at initial plating density of 2 × 10
4
cells/60 mm dish for 0 to 72 h. Cells were harvested at the indicated
time points and counted using an automated cell counter. Population
doubling times were calculated using Doubling Time Software v1.0.10
http://www.doubling-time.com.
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